logo
FDA Announces Recall of More Than 10,000 Cans of Coca-Cola for Potential Plastic Contamination

FDA Announces Recall of More Than 10,000 Cans of Coca-Cola for Potential Plastic Contamination

Yahoo25-03-2025

Over 10,000 cans of Original Coca-Cola have been recalled due to the potential presence of a foreign material, specifically plastic. The recall was initiated by a Coca-Cola manufacturer on March 6 and the U.S. Food & Drug Administration (FDA) classified the recall on March 24. 864 12-packs of Coca-Cola cans have been recalled in total.
The FDA declared it a 'Class II' recall, meaning the product has the potential to cause "temporary" or "reversible" health consequences.
The recall impacts specific cans of Coca-Cola that were manufactured by Reyes Coca-Cola Bottling, LLC out of Milwaukee, Wisconsin. Only a certain batch of 12-ounce Coca-Cola Original cans that were distributed in Illinois and Wisconsin are impacted by this recall.
To determine whether you have the recalled Coke, you'll want to look for the following information on the can or box:
Can UPC: 0 49000-00634 6
Pack UPC: UPC 0 49000-02890 4
Date Code: SEP2925MDA
Time Stamp: 1100-1253
'Canned Under Authority of the Coca-Cola Company, Atlanta, GA 30313'
No other Coca-Cola cans or products have been recalled at this time.
Because the recall was initiated in early March, it's likely that all the recalled products have been pulled from retailer shelves. However, if you have the recalled Coca-Cola product, do not consume it. Instead, throw it away or return it to the original place of purchase for a full refund or replacement.
Read the original article on ALLRECIPES

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Argenx presents new Efgartigimod data at EULAR 2025
Argenx presents new Efgartigimod data at EULAR 2025

Business Insider

timean hour ago

  • Business Insider

Argenx presents new Efgartigimod data at EULAR 2025

argenx (ARGX) SE 'announced the presentation of positive results from Phase 2 studies evaluating VYVGART in Sjogren's disease and idiopathic inflammatory myopathies at the European Congress of Rheumatology, EULAR 2025, from June 11 – 14 in Barcelona, Spain. argenx also announced that the FDA has granted efgartigimod Fast Track designation for the treatment of primary Sjogren's disease.' Confident Investing Starts Here: Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory
ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory

Yahoo

timean hour ago

  • Yahoo

ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory

We came across a bullish thesis on ClearPoint Neuro, Inc. (CLPT) on M.V. Cunha's Substack. In this article, we will summarize the bulls' thesis on CLPT. ClearPoint Neuro, Inc. (CLPT)'s share was trading at $13.93 as of 6th June. A medical doctor surrounded by advanced technology in the operating room. ClearPoint Neuro is transforming from a surgical tools provider into a critical platform company enabling the next generation of neurological treatments. In the first quarter of 2025, revenue grew 31 percent year-over-year to 8.5 million dollars, led by the rapid adoption of its SmartFrame operating room system, which increased 70 percent and allows hospitals to use ClearPoint technology in standard surgical settings. This expansion seeds a larger installed base and drives high-margin recurring revenue from disposable instruments. The biologics and drug delivery segment generated 4.7 million dollars in revenue, growing 9 percent year-over-year, and is supported by more than 60 active partnerships with gene and cell therapy developers. As these therapies move toward commercial use, ClearPoint's role as the enabling delivery infrastructure could become its most profitable revenue stream, with each procedure generating over 20,000 dollars in high-margin recurring revenue. Meanwhile, the company is intentionally moving away from capital equipment sales, which declined 63 percent, in favor of a subscription-based model that provides predictable recurring revenue. Operating cash burn fell 35 percent in 2024, with expenses rising 29 percent in the latest quarter due to targeted investments in preclinical services, therapy support, and device innovation. ClearPoint closed the quarter with 12.4 million dollars in cash and access to up to 105 million dollars in financing, providing sufficient capital to reach financial breakeven without near-term equity dilution. While risks around execution, partner dependency, and regulatory pacing remain, ClearPoint's embedded position across neurological therapy development offers investors a unique opportunity to benefit from a long-term transformation into the backbone of next-generation brain treatments. Previously, we highlighted a on ClearPoint Neuro from northeasternsvf in January 2025, which emphasized its unique position as the only FDA-cleared, MRI-guided neurosurgical platform enabling precise delivery of CNS gene and cell therapies. That thesis focused on the company's expanding biopharma partnerships, operating room penetration through SmartFrame OR, and its path to profitability via high-margin disposables. ClearPoint Neuro, Inc. (CLPT) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held CLPT at the end of the first quarter which was 13 in the previous quarter. While we acknowledge the risk and potential of CLPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CLPT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.

Recall alert: Over 19,000 cans of Dr Pepper Zero Sugar recalled for containing sugar
Recall alert: Over 19,000 cans of Dr Pepper Zero Sugar recalled for containing sugar

Yahoo

time5 hours ago

  • Yahoo

Recall alert: Over 19,000 cans of Dr Pepper Zero Sugar recalled for containing sugar

​​Over 19,000 cases of Dr Pepper Zero Sugar are being recalled after the cans were found to contain full-sugar soda, the U.S. Food and Drug Administration announced. The voluntary recall issued on May 23 affects the 12-ounce aluminum cans of a 12-pack and 24-pack case of Dr Pepper Zero Sugar. 'Product labeled to be zero sugar contains full sugar product,' the FDA wrote about the drink. The recalled product contains the same amount of sugar found in regular Dr Pepper, which is 39 grams per can. The recalled cans have the product code XXXXRS05165 with a 'best by' date of February 16, 2026. The cans were made by Pepsi Beverages Company in Jacksonville, Florida and distributed to only Florida, Georgia and South Carolina. On June 5, the FDA then classified the product as a class II recall. This level of recall is 'a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote,' according to the FDA. See the full recall here. Recall alert: These window air conditioners could cause mold exposure Recall alert: Bring these crackers back to the store due to undeclared allergen Recall alert: Throw away these 17 salads, salsas due to salmonella concern Read the original article on MassLive.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store